BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, Azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with Tirzepatide to potentially become a groundbreaking treatment for obesity in the elderly.